AwesomeCapital
Search This Blog
Friday, April 5, 2019
Stephens Reiterates Overweight Rating on Myriad Genetics
Stephens analyst Drew Jones reiterated an Overweight rating and $52 target price.
https://www.streetinsider.com/Analyst+Comments/Stephens+Reiterates+Overweight+Rating+on+Myriad+Genetics+%28MYGN%29/15344760.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.